Infinity Biologix LLC

Infinity Biologix LLC, operating as the Sampled Division and headquartered in Piscataway, New Jersey, delivers advanced genomic analysis, DNA sequencing, genotyping, next-generation sequencing, and biorepository solutions to federal research agencies as a prime contractor (60% of recent awards) and as a subcontractor on grant-funded biomedical research programs. The company is a for-profit limited liability partnership with no SBA set-aside certifications; it competes full-and-open across its prime footprint, though one small-business-set-aside IDIQ with the Department of Agriculture's Agricultural Research Service anchors a minor vehicle.

Infinity Biologix's customer concentration is dominated by health research agencies. The National Institutes of Health and the Department of Veterans Affairs account for the majority of potential value across five distinct federal agencies. The National Cancer Institute alone funds $149.2 million in combined potential value through a single indefinite delivery contract (IDC) awarded January 13, 2025, for genome characterization center services including large-scale whole exome sequencing and array platforms, running through January 12, 2030. VA Headquarters follows with eight awards totaling $91.5 million, driven primarily by delivery orders for genomic analysis services issued between 2021 and 2024. The National Institute on Drug Abuse maintains a $15 million single-award IDC (awarded March 14, 2023, through March 13, 2028) for the NIDA Center for Genetic Studies, encompassing DNA/RNA sequencing, epigenetic analyses, cell line development, and biospecimen repository management; three delivery orders under this vehicle total $5.7 million. Veterans Integrated Service Network 1 issued a $27.1 million single-award IDIQ on March 2, 2026, for long-read sequencing supporting the VA's Million Veteran Program, with ultimate completion March 1, 2031 and two delivery orders already issued ($7.8 million and $1.2 million). Recent prime work includes $6.3 million and $4.4 million delivery orders from VA Headquarters for genomic analysis (2023–2024), a $6.3 million HHS genomic analysis delivery order (2025), and a $171.8 thousand purchase order from the National Institute of Allergy and Infectious Diseases for whole genome sequencing (2024).

Awards per year have grown from one in 2022 to ten in 2024, with nine awards in 2025 and six in 2026 year-to-date. Three awards carrying combined potential value of $11.9 million reach ultimate completion inside the next twenty-four months, triggering recompete or task-order renewal activity on VA and CDC work. The vendor's top parent IDVs are the NCI Genomic Characterization Centers contract (seven task orders, $54.5 million), a CDC or HHS vehicle (two task orders, $9 million), and the VA IDIQ (two task orders, $5.7 million). In its subcontractor role, Infinity Biologix provides biospecimen storage and laboratory services under prime contracts held by Guidehouse Digital LLC, New Tech Solutions Inc., and Axle Informatics on NIDA's Developmental Studies Biorepository and Analysis Center program (task orders awarded 2024–2025). The vendor also subcontracts on federal grant programs, delivering kit production for the Immune Tolerance Network clinical trials under Benaroya Research Institute subawards, genomic studies support to Rutgers University's Center for Genomic Studies on Mental Disorders, and data coordinating services to University of South Florida's Type 1 Diabetes TrialNet—all NIH-funded research initiatives with recurring subaward activity through 2026. The vendor's footprint centers exclusively on civilian research and health-mission work; combined obligated dollars across all awards stand at $110 million against combined potential value of $307.6 million.